Back to Search
Start Over
Membrane Lipid Replacement for reconstituting mitochondrial function and moderating cancer-related fatigue, pain and other symptoms while counteracting the adverse effects of cancer cytotoxic therapy.
- Source :
-
Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Jun; Vol. 41 (3), pp. 199-217. Date of Electronic Publication: 2024 Jun 16. - Publication Year :
- 2024
-
Abstract
- Cancer-related fatigue, pain, gastrointestinal and other symptoms are among the most familiar complaints in practically every type and stage of cancer, especially metastatic cancers. Such symptoms are also related to cancer oxidative stress and the damage instigated by cancer cytotoxic therapies to cellular membranes, especially mitochondrial membranes. Cancer cytotoxic therapies (chemotherapy and radiotherapy) often cause adverse symptoms and induce patients to terminate their anti-neoplastic regimens. Cancer-related fatigue, pain and other symptoms and the adverse effects of cancer cytotoxic therapies can be safely moderated with oral Membrane Lipid Replacement (MLR) glycerolphospholipids and mitochondrial cofactors, such as coenzyme Q <subscript>10</subscript> . MLR provides essential membrane lipids and precursors to maintain mitochondrial and other cellular membrane functions and reduces fatigue, pain, gastrointestinal, inflammation and other symptoms. In addition, patients with a variety of chronic symptoms benefit from MLR supplements, and MLR also has the ability to enhance the bioavailability of nutrients and slowly remove toxic, hydrophobic molecules from cells and tissues.<br /> (© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
- Subjects :
- Humans
Antineoplastic Agents adverse effects
Ubiquinone analogs & derivatives
Ubiquinone therapeutic use
Cancer Pain drug therapy
Cancer Pain etiology
Neoplasms drug therapy
Neoplasms complications
Mitochondria drug effects
Fatigue etiology
Fatigue chemically induced
Membrane Lipids metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1573-7276
- Volume :
- 41
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Clinical & experimental metastasis
- Publication Type :
- Academic Journal
- Accession number :
- 38879842
- Full Text :
- https://doi.org/10.1007/s10585-024-10290-6